Cirrhosis and Sarcopenia

Abstract

Sarcopenia is a progressive muscle wasting syndrome involving loss in skeletal muscle mass, strength, and function. It is closely associated with cirrhosis and its complications with up to more than half of cirrhotic patients demonstrating imaging findings of sarcopenia. The pathogenesis of this syndrome remains complex, including multiple factors involved in skeletal muscle homeostasis, systemic inflammation, and energy dysregulation. Many modalities exist in assessing and measuring sarcopenia. The use of cross-sectional imaging, such as computed tomography and magnetic resonance imaging, with accurate and clinically proven assessment software should be considered the gold standard. Sarcopenia has become the focus of ongoing extensive research with initial findings highlighting increased mortality and complication rates in patient with cirrhosis and hepatocellular carcinoma. Additional studies have demonstrated reversal and improved survival in sarcopenic patients who have undergone transjugular intrahepatic portosystemic shunt placement. Thus, accounting for sarcopenia can help risk stratify patients prior to interventional procedures to allow for better outcomes and improved survival.

Keywords

sarcopenia - cirrhosis - computed tomography - transjugular intrahepatic portosystemic shunt - interventional radiology

Disclosures

This study was not supported by any funding. The author(s) received no financial support for the preparation of this article for publication. The authors have no disclosures.

Publikationsverlauf

Artikel online veröffentlicht:
04. Mai 2023

• References

• 1 Tapper EB, Aberasturi D, Zhao Z, Hsu CY, Parikh ND. Outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis. Aliment Pharmacol Ther 2020; 51 (12) 1397-1405
• 2 Tandon P, Montano-Loza AJ, Lai JC, Dasarathy S, Merli M. Sarcopenia and frailty in decompensated cirrhosis. J Hepatol 2021; 75 Suppl 1 (Suppl. 01) S147-S162
• 3 Anand AC. Nutrition and muscle in cirrhosis. J Clin Exp Hepatol 2017; 7 (04) 340-357
• 4 Warner II ER, Aloor FZ, Satapathy SK. A narrative review of nutritional abnormalities, complications, and optimization in the cirrhotic patient. Transl Gastroenterol Hepatol 2022; 7: 5-5
• 5 Periyalwar P, Dasarathy S. Malnutrition in cirrhosis: contribution and consequences of sarcopenia on metabolic and clinical responses. Clin Liver Dis 2012; 16 (01) 95-131
• 6 Farshad O, Ommati M, Alizadeh S. et al. Skeletal muscle mitochondrial impairment in cirrhosis-induced sarcopenia. Trends Pharmacol Sci 2020; 6 (03) 189-204
• 7 Rodriguez J, Vernus B, Chelh I. et al. Myostatin and the skeletal muscle atrophy and hypertrophy signaling pathways. Cell Mol Life Sci 2014; 71 (22) 4361-4371
• 8 Welch N, Dasarathy J, Runkana A. et al. Continued muscle loss increases mortality in cirrhosis: impact of aetiology of liver disease. Liver Int 2020; 40 (05) 1178-1188
• 9 Montano-Loza AJ, Meza-Junco J, Baracos VE. et al. Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation. Liver Transpl 2014; 20 (06) 640-648
• 10 DiMartini A, Cruz Jr RJ, Dew MA. et al. Muscle mass predicts outcomes following liver transplantation. Liver Transpl 2013; 19 (11) 1172-1180
• 11 Nardelli S, Lattanzi B, Torrisi S. et al. Sarcopenia is risk factor for development of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement. Clin Gastroenterol Hepatol 2017; 15 (06) 934-936
• 12 Hanai T, Shiraki M, Nishimura K. et al. Sarcopenia impairs prognosis of patients with liver cirrhosis. Nutrition 2015; 31 (01) 193-199
• 13 Batsis JA, Villareal DT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nat Rev Endocrinol 2018; 14 (09) 513-537
• 14 Kappus MR, Mendoza MS, Nguyen D, Medici V, McClave SA. Sarcopenia in patients with chronic liver disease: Can it be altered by diet and exercise?. Curr Gastroenterol Rep 2016; 18 (08) 43
• 15 West J, Gow PJ, Testro A, Chapman B, Sinclair M. Exercise physiology in cirrhosis and the potential benefits of exercise interventions: a review. J Gastroenterol Hepatol 2021; 36 (10) 2687-2705
• 16 Fox R, Stenning K, Slee A, Macnaughtan J, Davies N. Sarcopenia in liver cirrhosis: prevalence, pathophysiology and therapeutic strategies. Anal Biochem 2022; 647: 114581
• 17 Lai JC, Tandon P, Bernal W. et al. Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2021; 74 (03) 1611-1644
• 18 Aqel BA, Scolapio JS, Dickson RC, Burton DD, Bouras EP. Contribution of ascites to impaired gastric function and nutritional intake in patients with cirrhosis and ascites. Clin Gastroenterol Hepatol 2005; 3 (11) 1095-1100
• 19 Dolz C, Raurich JM, Ibáñez J, Obrador A, Marsé P, Gayá J. Ascites increases the resting energy expenditure in liver cirrhosis. Gastroenterology 1991; 100 (03) 738-744
• 20 Lang CH, Frost RA, Svanberg E, Vary TC. IGF-I/IGFBP-3 ameliorates alterations in protein synthesis, eIF4E availability, and myostatin in alcohol-fed rats. Am J Physiol Endocrinol Metab 2004; 286 (06) E916-E926
• 21 Thapaliya S, Runkana A, McMullen MR. et al. Alcohol-induced autophagy contributes to loss in skeletal muscle mass. Autophagy 2014; 10 (04) 677-690
• 22 Bousquet-Dubouch MP, Nguen S, Bouyssié D. et al. Chronic ethanol feeding affects proteasome-interacting proteins. Proteomics 2009; 9 (13) 3609-3622
• 23 Abrigo J, Gonzalez F, Aguirre F. et al. Cholic acid and deoxycholic acid induce skeletal muscle atrophy through a mechanism dependent on TGR5 receptor. J Cell Physiol 2021; 236 (01) 260-272
• 24 Bhanji RA, Narayanan P, Allen AM, Malhi H, Watt KD. Sarcopenia in hiding: the risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis. Hepatology 2017; 66 (06) 2055-2065
• 25 Kim HY, Jang JW. Sarcopenia in the prognosis of cirrhosis: going beyond the MELD score. World J Gastroenterol 2015; 21 (25) 7637-7647
• 26 Dhaliwal A, Armstrong MJ. Sarcopenia in cirrhosis: a practical overview. Clin Med (Lond) 2020; 20 (05) 489-492
• 27 Ooi PH, Hager A, Mazurak VC. et al. Sarcopenia in chronic liver disease: impact on outcomes. Liver Transpl 2019; 25 (09) 1422-1438
• 28 Bhanji RA, Montano-Loza AJ, Watt KD. Sarcopenia in cirrhosis: looking beyond the skeletal muscle loss to see the systemic disease. Hepatology 2019; 70 (06) 2193-2203
• 29 Liu J, Ma J, Yang C. et al. Sarcopenia in patients with cirrhosis after transjugular intrahepatic portosystemic shunt placement. Radiology 2022; 303 (03) 711-719
• 30 Tantai X, Liu Y, Yeo YH. et al. Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysis. J Hepatol 2022; 76 (03) 588-599
• 31 Ebadi M, Bhanji RA, Mazurak VC, Montano-Loza AJ. Sarcopenia in cirrhosis: from pathogenesis to interventions. J Gastroenterol 2019; 54 (10) 845-859
• 32 Merli M, Berzigotti A, Zelber-Sagi S. et al; European Association for the Study of the Liver. Electronic address: [e-mail], European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol 2019; 70 (01) 172-193
• 33 Cruz-Jentoft AJ, Landi F, Schneider SM. et al. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age Ageing 2014; 43 (06) 748-759
• 34 Carey EJ, Lai JC, Wang CW. et al; Fitness, Life Enhancement, and Exercise in Liver Transplantation Consortium. A multicenter study to define sarcopenia in patients with end-stage liver disease. Liver Transpl 2017; 23 (05) 625-633
• 35 Irving BA, Weltman JY, Brock DW, Davis CK, Gaesser GA, Weltman A. NIH ImageJ and Slice-O-Matic computed tomography imaging software to quantify soft tissue. Obesity (Silver Spring) 2007; 15 (02) 370-376
• 36 Shen W, Punyanitya M, Wang Z. et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol 2004; 97 (06) 2333-2338
• 37 Merli M, Giusto M, Gentili F. et al. Nutritional status: its influence on the outcome of patients undergoing liver transplantation. Liver Int 2010; 30 (02) 208-214
• 38 Durand F, Buyse S, Francoz C. et al. Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography. J Hepatol 2014; 60 (06) 1151-1157
• 39 Kim G, Kang SH, Kim MY, Baik SK. Prognostic value of sarcopenia in patients with liver cirrhosis: a systematic review and meta-analysis. PLoS One 2017; 12 (10) e0186990
• 40 Kalafateli M, Mantzoukis K, Choi Yau Y. et al. Malnutrition and sarcopenia predict post-liver transplantation outcomes independently of the model for end-stage liver disease score. J Cachexia Sarcopenia Muscle 2017; 8 (01) 113-121
• 41 Kang SH, Jeong WK, Baik SK, Cha SH, Kim MY. Impact of sarcopenia on prognostic value of cirrhosis: going beyond the hepatic venous pressure gradient and MELD score. J Cachexia Sarcopenia Muscle 2018; 9 (05) 860-870
• 42 Bunchorntavakul C, Reddy KR. Review article: malnutrition/sarcopenia and frailty in patients with cirrhosis. Aliment Pharmacol Ther 2020; 51 (01) 64-77
• 43 Voron T, Tselikas L, Pietrasz D. et al. Sarcopenia impacts on short- and long-term results of hepatectomy for hepatocellular carcinoma. Ann Surg 2015; 261 (06) 1173-1183
• 44 Kobayashi T, Kawai H, Nakano O. et al. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies. BMC Cancer 2018; 18 (01) 756
• 45 Engelmann C, Schob S, Nonnenmacher I. et al. Loss of paraspinal muscle mass is a gender-specific consequence of cirrhosis that predicts complications and death. Aliment Pharmacol Ther 2018; 48 (11-12): 1271-1281
• 46 Shirai H, Kaido T, Hamaguchi Y. et al. Preoperative low muscle mass has a strong negative effect on pulmonary function in patients undergoing living donor liver transplantation. Nutrition 2018; 45: 1-10
• 47 Harimoto N, Yoshizumi T, Izumi T. et al. Clinical outcomes of living liver transplantation according to the presence of sarcopenia as defined by skeletal muscle mass, hand grip, and gait speed. Transplant Proc 2017; 49 (09) 2144-2152
• 48 Chae MS, Moon KU, Jung JY. et al. Perioperative loss of psoas muscle is associated with patient survival in living donor liver transplantation. Liver Transpl 2018; 24 (05) 623-633
• 49 Hung ML, Lee EW. Role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension: review and update of the literature. Clin Liver Dis 2019; 23 (04) 737-754
• 50 Schindler P, Heinzow H, Trebicka J, Wildgruber M. Shunt-induced hepatic encephalopathy in TIPS: current approaches and clinical challenges. J Clin Med 2020; 9 (11) 3784
• 51 Merli M, Giusto M, Lucidi C. et al. Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study. Metab Brain Dis 2013; 28 (02) 281-284
• 52 Masuda T, Shirabe K, Ikegami T. et al. Sarcopenia is a prognostic factor in living donor liver transplantation. Liver Transpl 2014; 20 (04) 401-407
• 53 van Vugt JL, Levolger S, de Bruin RW, van Rosmalen J, Metselaar HJ, IJzermans JN. Systematic review and meta-analysis of the impact of computed tomography-assessed skeletal muscle mass on outcome in patients awaiting or undergoing liver transplantation. Am J Transplant 2016; 16 (08) 2277-2292
• 54 Praktiknjo M, Book M, Luetkens J. et al. Fat-free muscle mass in magnetic resonance imaging predicts acute-on-chronic liver failure and survival in decompensated cirrhosis. Hepatology 2018; 67 (03) 1014-1026
• 55 Bai YW, Liu JC, Yang CT. et al. Inclusion of sarcopenia improves the prognostic value of MELD score in patients after transjugular intrahepatic portosystemic shunt. Eur J Gastroenterol Hepatol 2022; 34 (09) 948-955
• 56 Dasarathy J, Alkhouri N, Dasarathy S. Changes in body composition after transjugular intrahepatic portosystemic stent in cirrhosis: a critical review of literature. Liver Int 2011; 31 (09) 1250-1258
• 57 Jahangiri Y, Pathak P, Tomozawa Y, Li L, Schlansky BL, Farsad K. Muscle gain after transjugular intrahepatic portosystemic shunt creation: time course and prognostic implications for survival in cirrhosis. J Vasc Interv Radiol 2019; 30 (06) 866-872.e4
• 58 Gioia S, Merli M, Nardelli S. et al. The modification of quantity and quality of muscle mass improves the cognitive impairment after TIPS. Liver Int 2019; 39 (05) 871-877
• 59 Bureau C, Thabut D, Oberti F. et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology 2017; 152 (01) 157-163
• 60 Narahara Y, Kanazawa H, Fukuda T. et al. Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial. J Gastroenterol 2011; 46 (01) 78-85